It is important that they do. Not only are clinical diagnostic laboratories revenue drivers for healthcare institutions, but also as personalized medicine becomes “standard medicine,” diagnostic laboratories and clinical pathologists will be the control point of that extensive clinical data. These same lab testing technologies increasingly position the pathologist or geneticist to offer guidance to physicians about the most appropriate therapies for their patients.
Pathology’s forward thinkers define molecular diagnostics and genetic testing as both the future of pathology and the #1 opportunity to add clinical value while earning appropriate reimbursement. But for pathologists to realize this potential and convert it into reality, they must have the right tools in place, including the ability to collect, store, retrieve, analyze, and report the data from molecular assays and genetic tests.
That is where Molecular Information Management Systems (MIMS) come into the picture. The Dark Report is pleased to offer this FREE White Paper—your key to unlocking the potential of molecular diagnostics to the benefit of your laboratory, and the contribution it can make to patient care.
This White Paper provides you with a detailed discussion regarding:
- An overview of the current state of the MIMS industry
- What a MIMS is and what a MIMS is not
- What a pathology lab needs to do to acquire and use a MIMS to advance patient care and increase revenue
- Smart ways to purchase MIMS and get the best ROI
- How to evaluate key factors for calculating ROI on MIMS
Table of Contents:
Why Every Pathology Lab Needs “MIMS,” an Information Management System for Molecular Test Data
Molecular Pathology’s Increasing Role in Personalized and Predictive Medicine and How It Creates Opportunities for Pathology Groups
What You Need to Know about MIMS, the Molecular Information Management System
MIMS as a Bioinformatics Resource: Understanding Automated Molecular Test Data Analysis and Its Role in Identifying Essential Factors as Pathologists Create Personalized Treatment Plans
MIMS in Support of Multi-Faceted Analysis: Unique and Specific Use of Molecular Test Data Elements Provide a Specific Combination of Unique Specialized Treatment Regimens
MIMS’ Role with Automated Molecular Testing Systems and Next-Generation Middleware
Adopting MIMS for Clinical Use
Molecular Technology Collaboration: The True Potential in Molecular Automation Will Not Evolve and Be Fully Realized Without Industry Participation
Personalized medicine and predictive medicine have become a reality. As a result, the need for a molecular information management system will become increasingly important; specifically, robust, best-in-breed MIMS that can handle the complex workflows of various molecular platforms and modalities, and accommodate the large data volume, digital imaging and complex reporting needs that personalized medicine will require.
This White Paper discusses the trends in increasing use of genetic and molecular testing, the growth of big data in healthcare, and the challenges facing laboratories in handling the complexities of personalized medicine. It also outlines considerations when purchasing a MIMS, and challenges for MIMS and other HIT vendors in terms of compatibility between various HIT technologies.
Download the White Paper now by completing the form below.